Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin

Ridinilazole, a novel targeted antibacterial being developed for the treatment of C. difficile infection (CDI) and prevention of recurrence, was shown in a recent Phase 2 study to be superior to vancomycin with regard to the primary efficacy measure, sustained clinical response (SCR), with the super...

Descripción completa

Detalles Bibliográficos
Autores principales: Thorpe, Cheleste M., Kane, Anne V., Chang, Justin, Tai, Albert, Vickers, Richard J., Snydman, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071993/
https://www.ncbi.nlm.nih.gov/pubmed/30071046
http://dx.doi.org/10.1371/journal.pone.0199810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071993/
https://www.ncbi.nlm.nih.gov/pubmed/30071046
http://dx.doi.org/10.1371/journal.pone.0199810

Ejemplares similares